Retatrutide: A triple hormone receptor agonist for obesity

Nature Medicine·2023·Jastreboff AM et al.·Nature Medicine

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 clinical data show substantial weight reduction in adults with obesity, with effects exceeding those of dual agonists in the same trial period. Researchers note the glucagon receptor component may contribute additional metabolic effects beyond appetite suppression.

Why this research is interesting

This study is among the first to report clinical results for a triple receptor agonist in humans, extending the dual GLP-1/GIP approach by adding glucagon receptor activity. It represents a meaningful step in understanding whether multi-receptor agonism can produce greater weight loss than current therapies.

What the research says

In a Phase 2 trial, participants receiving retatrutide achieved mean weight reductions of approximately 17% at 48 weeks at higher doses, with dose-dependent responses across treatment arms. The trial enrolled adults with obesity, with and without type 2 diabetes.

What the evidence shows

This is a Phase 2 clinical trial — a controlled human study, but not yet a confirmatory Phase 3 trial. The sample size was moderate and the duration was under one year. Results support further investigation but do not establish the drug as approved or definitively safe for long-term use.

What remains uncertain

Long-term safety, durability of weight loss after discontinuation, effects in broader populations, and direct head-to-head comparison with tirzepatide remain to be determined. The contribution of the glucagon receptor component specifically is difficult to isolate from the combined mechanism.